ImmuCell (NASDAQ:ICCC) CEO Boekhorst Paul Francis Oliv Te Acquires 8,000 Shares of Stock

ImmuCell Corporation (NASDAQ:ICCC) CEO Boekhorst Paul Francis Oliv Te acquired 8,000 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The shares were acquired at an average price of $9.49 per share, with a total value of $75,920.00. Following the acquisition, the chief executive officer owned 17,785 shares in the company, valued at $168,779.65. This trade represents a 81.76% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

ImmuCell Stock Performance

ICCC stock opened at $9.74 on Tuesday. The company has a quick ratio of 2.60, a current ratio of 4.82 and a debt-to-equity ratio of 0.24. The business’s fifty day simple moving average is $9.02 and its two-hundred day simple moving average is $7.25. ImmuCell Corporation has a twelve month low of $4.52 and a twelve month high of $10.75. The firm has a market cap of $88.15 million, a price-to-earnings ratio of -162.31 and a beta of 0.55.

ImmuCell (NASDAQ:ICCC) last issued its earnings results on Thursday, May 14th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.16. The firm had revenue of $10.36 million during the quarter, compared to analyst estimates of $5.40 million. ImmuCell had a negative net margin of 1.82% and a negative return on equity of 1.88%.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of ImmuCell from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Monday, April 6th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ICCC. Geode Capital Management LLC raised its position in shares of ImmuCell by 4.2% in the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock worth $500,000 after acquiring an additional 2,907 shares in the last quarter. Steadtrust LLC bought a new stake in ImmuCell during the third quarter valued at about $198,000. Mesirow Financial Investment Management Inc. boosted its position in ImmuCell by 199.6% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock valued at $224,000 after purchasing an additional 24,303 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in ImmuCell by 3.2% in the first quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 1,749 shares during the last quarter. Finally, Militia Capital Management LLC purchased a new position in ImmuCell in the first quarter valued at about $114,000. 13.47% of the stock is currently owned by hedge funds and other institutional investors.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.